Publications by authors named "Suneel D Mundle"

Claim this Profile
N
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.
Gerhardt Attard, Neeraj Agarwal, Julie N Graff, Shahneen Sandhu, Eleni Efstathiou, Suneel D Mundle

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN.
Alejo Rodriguez-Vida, Angel Borque, Fernando Lopez-Campos, Alvaro Juarez Soto, Beatriz Garcillan, Suneel D Mundle

Eur Urol Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-Metastasis Survival of Patients with High-Risk Localized and Locally Advanced Prostate Cancer Undergoing Primary Treatment in the United States: A Retrospective Study.
Stephen J Freedland, Luis Fernandes, Francesco De Solda, Nasuh Buyukkaramikli, Suneel D Mundle

Target Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review.
Benjamin A Gartrell, Angaja Phalguni, Paulina Bajko, Suneel D Mundle, Sharon A McCarthy

Eur Urol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.
Axel S Merseburger, Neeraj Agarwal, Anders Bjartell, Hirotsugu Uemura, Alvaro Juarez Soto, Suneel D Mundle

BJU Int· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
Eric J Small, Kim N Chi, Simon Chowdhury, Katherine B Bevans, Amitabha Bhaumik, Suneel D Mundle

Eur Urol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population-based study of disease trajectory after radical treatment for high-risk prostate cancer.
Pär Stattin, Sarah Fleming, Xiwu Lin, Florence Lefresne, Sabine D Brookman-May, Suneel D Mundle

BJU Int· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
Manuel Weber, Wolfgang P Fendler, Aravind S Ravi Kumar, Jeremie Calais, Johannes Czernin, Suneel D Mundle

Eur Urol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Simon Chowdhury, Anders Bjartell, Neeraj Agarwal, Byung H Chung, Robert W Given, Suneel D Mundle

Future Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
John Shen, Simon Chowdhury, Neeraj Agarwal, Lawrence I Karsh, Stéphane Oudard, Suneel D Mundle

Br J Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
YaoYao Pollock, Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Suneel D Mundle

Prostate Cancer Prostatic Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients.
Stephen J Freedland, Sandhya Nair, Xiwu Lin, Lawrence Karsh, Christopher Pieczonka, Suneel D Mundle

World J Urol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.
Axel S Merseburger, Neeraj Agarwal, Amitabha Bhaumik, Florence Lefresne, Laurence I Karsh, Suneel D Mundle

Eur J Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
YaoYao Pollock, Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Suneel D Mundle

Prostate Cancer Prostatic Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Fred Saad, Eric J Small, Felix Y Feng, Julie N Graff, David Olmos, Suneel D Mundle

Eur Urol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Fred Saad, Eleni Efstathiou, Gerhardt Attard, Thomas W Flaig, Fabio Franke, Suneel D Mundle

Lancet Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Kim N Chi, Simon Chowdhury, Anders Bjartell, Byung Ha Chung, Andrea J Pereira de Santana Gomes, Suneel D Mundle

J Clin Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mathematical modeling of bone marrow - peripheral blood dynamics in the disease state based on current emerging paradigms, part II.
Evans K Afenya, Rachid Ouifki, Suneel D Mundle

J Theor Biol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mathematical modeling of bone marrow--peripheral blood dynamics in the disease state based on current emerging paradigms, part I.
Evans K Afenya, Rachid Ouifki, Baba I Camara, Suneel D Mundle

Math Biosci· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In reply.
Richard J Auchus, Margaret K Yu, Suzanne Nguyen, Suneel D Mundle

Oncologist· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
Richard J Auchus, Margaret K Yu, Suzanne Nguyen, Suneel D Mundle

Oncologist· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transient therapy-related surge in serum tumor biomarkers: characterizing behavior and postulating its biologic role.
Suneel D Mundle, Anuj S Marathe, Mohan Chelladurai

Crit Rev Oncol Hematol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting cyclin D1 for high risk myelodysplastic syndromes.
Suneel D Mundle

Leuk Res· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes.
Suneel D Mundle

Future Oncol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in erythropoietic growth factor therapy for myelodysplastic syndromes.
Suneel D Mundle

Expert Opin Biol Ther· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis